Phase 2 Study of Neoadjuvant Enzalutamide and Paclitaxel for Luminal Androgen Receptor-Enriched TNBC: Trial Results and Insights into “Arness”
Cell Reports Medicine(2024)
Key words
triple-negative breast cancer,androgen receptor,enzalutamide,ARness,biomarker of response,LAR subtype,TNBC,neoadjuvant systemic therapy
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined